NewcelX Files to Sell 2.26M Common Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Should l Buy NCEL?
NewcelX files to sell 2.26M common shares for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NCEL
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NLS Pharmaceutics Reports FY 2025 Financial Results
- Financial Overview: NLS Pharmaceutics reported a GAAP EPS of -$2.16 for FY 2025, indicating ongoing financial losses that reflect the company's pressures and challenges in market competition.
- Cash Position: As of December 31, 2025, the company had $2.2 million in cash and cash equivalents, suggesting a tight liquidity situation that may impact future operational and investment decisions.
- Net Loss Breakdown: The net loss for 2025 was $8.3 million, including $5.7 million in non-cash accounting-related finance expenses primarily linked to the fair value remeasurement of convertible instruments, which are not expected to recur, potentially improving future financial conditions.
- Operating Cash Flow: The net cash used in operating activities was $2.8 million, reflecting increased investments in NCEL-101 development activities, which, while increasing short-term financial pressure, may enhance product development and market competitiveness in the long run.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
NewcelX Announces Private Placement at 30% Premium, Stock Rises
- Private Placement Agreement: NewcelX announced a private placement at $2.75 per share, representing a 30% premium to the last closing price on March 31, 2026, indicating strong market confidence in the company's future.
- Shares and Warrants: The offering includes the sale of 490,907 common shares and warrants for 687,270 common shares at $3.025 each, expected to close around April 15, 2026, enhancing the company's capital structure.
- Clear Use of Proceeds: The company intends to use the net proceeds along with its previously announced $25 million equity line to advance NCEL-101, its lead program for Type 1 Diabetes, demonstrating a focus on core projects.
- Active Shareholder Participation: The offering includes participation from existing shareholders, reflecting investor recognition of the company's growth potential while providing funding support for operations and other development initiatives.
See More
NewcelX Secures Strong Financing to Advance Type 1 Diabetes Program
- Financing Details: NewcelX has entered into securities purchase agreements for a private placement at $2.75 per share, selling 490,907 common shares at a 30% premium to the last closing price, reflecting strong investor confidence in the company.
- Use of Proceeds: The net proceeds from this offering will be combined with a previously announced $25 million equity line to advance NCEL-101, NewcelX's lead program aimed at potentially curing Type 1 Diabetes, thereby enhancing the company's competitive position in the biopharmaceutical sector.
- Investor Participation: The offering includes participation from existing shareholders, reinforcing trust in the company's strategy and the potential of NCEL-101 to address significant unmet needs in Type 1 Diabetes, which is crucial for long-term growth.
- Compliance Statement: The securities are issued under Section 4(a)(2) of the Securities Act, ensuring compliance and reducing legal risks, which enhances investor confidence in the company's future developments.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaboration agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, which is expected to accelerate clinical timelines and optimize regulatory pathways.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients provides crucial data support for the development of NCEL-101, which not only enhances the efficacy of cell replacement therapies but may also streamline the regulatory approval process, thereby expediting the product's market entry.
- Core Product Positioning: NCEL-101, as NewcelX's core therapeutic product, aims to address the shortage of functional insulin-producing cells through scalable, off-the-shelf manufacturing, with the integration of immune modulation intended to enhance cell survival and durability, thereby improving treatment outcomes.
- Strategic Milestone: NewcelX's Chief Scientific Officer Michel Revel stated that this collaboration marks an important strategic milestone for the company in executing clinical programs, and is expected to enhance partnerships with leaders in immune biology and transplant medicine, ultimately driving long-term shareholder value.
See More
NLS Pharmaceutics Reports FY 2025 Financial Results
- Financial Overview: NLS Pharmaceutics reported a GAAP EPS of -$2.16 for FY 2025, indicating ongoing financial losses that reflect the company's pressures and challenges in market competition.
- Cash Position: As of December 31, 2025, the company had $2.2 million in cash and cash equivalents, suggesting a tight liquidity situation that may impact future operational and investment decisions.
- Net Loss Breakdown: The net loss for 2025 was $8.3 million, including $5.7 million in non-cash accounting-related finance expenses primarily linked to the fair value remeasurement of convertible instruments, which are not expected to recur, potentially improving future financial conditions.
- Operating Cash Flow: The net cash used in operating activities was $2.8 million, reflecting increased investments in NCEL-101 development activities, which, while increasing short-term financial pressure, may enhance product development and market competitiveness in the long run.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
NewcelX Announces Private Placement at 30% Premium, Stock Rises
- Private Placement Agreement: NewcelX announced a private placement at $2.75 per share, representing a 30% premium to the last closing price on March 31, 2026, indicating strong market confidence in the company's future.
- Shares and Warrants: The offering includes the sale of 490,907 common shares and warrants for 687,270 common shares at $3.025 each, expected to close around April 15, 2026, enhancing the company's capital structure.
- Clear Use of Proceeds: The company intends to use the net proceeds along with its previously announced $25 million equity line to advance NCEL-101, its lead program for Type 1 Diabetes, demonstrating a focus on core projects.
- Active Shareholder Participation: The offering includes participation from existing shareholders, reflecting investor recognition of the company's growth potential while providing funding support for operations and other development initiatives.
See More
NewcelX Secures Strong Financing to Advance Type 1 Diabetes Program
- Financing Details: NewcelX has entered into securities purchase agreements for a private placement at $2.75 per share, selling 490,907 common shares at a 30% premium to the last closing price, reflecting strong investor confidence in the company.
- Use of Proceeds: The net proceeds from this offering will be combined with a previously announced $25 million equity line to advance NCEL-101, NewcelX's lead program aimed at potentially curing Type 1 Diabetes, thereby enhancing the company's competitive position in the biopharmaceutical sector.
- Investor Participation: The offering includes participation from existing shareholders, reinforcing trust in the company's strategy and the potential of NCEL-101 to address significant unmet needs in Type 1 Diabetes, which is crucial for long-term growth.
- Compliance Statement: The securities are issued under Section 4(a)(2) of the Securities Act, ensuring compliance and reducing legal risks, which enhances investor confidence in the company's future developments.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaboration agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, which is expected to accelerate clinical timelines and optimize regulatory pathways.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients provides crucial data support for the development of NCEL-101, which not only enhances the efficacy of cell replacement therapies but may also streamline the regulatory approval process, thereby expediting the product's market entry.
- Core Product Positioning: NCEL-101, as NewcelX's core therapeutic product, aims to address the shortage of functional insulin-producing cells through scalable, off-the-shelf manufacturing, with the integration of immune modulation intended to enhance cell survival and durability, thereby improving treatment outcomes.
- Strategic Milestone: NewcelX's Chief Scientific Officer Michel Revel stated that this collaboration marks an important strategic milestone for the company in executing clinical programs, and is expected to enhance partnerships with leaders in immune biology and transplant medicine, ultimately driving long-term shareholder value.
See More
